New Report: 1 in 40 Kids Has Autism

New Study Reveals Vaccine Makers Fail to Test Safety of Aluminum Adjuvants Against Placebo
The Varicella Vaccine, Skyrocketing Shingles and CDC Chicanery
By the World Mercury Project Team
“Collusion” is the word du jour, and the practice’s very characteristics—deception, fraud, misrepresentation and secrecy—often prevent collusive acts from coming to light. In the scientific research community, would-be deceivers draw on a variety of tricks to slant their message, including manipulating data, employing other questionable research practices, not disclosing conflicts of interest, harassing whistleblowers and engaging in outright censorship.
The Centers for Disease Control and Prevention (CDC) is no stranger to any of these tactics, but eventually, as Shakespeare once predicted, the “truth will out.” Critics and senior scientists, in growing numbers, have been pulling back the veil on the CDC’s unethical modus operandi, arguing that questionable practices have become “the norm and not the rare exception.” Adding to this emerging picture of a public agency captive to “rogue interests,” a March 2018 article in the Annals of Clinical Pathology describes CDC’s suppression of inconvenient research findings pertaining to its Universal Varicella Vaccination Program. The author, an independent computer scientist, outlines in morbidly fascinating detail the “collusion” between CDC and its local public health partner to conceal unwanted chickenpox vaccine outcomes from the public.
One virus, two diseases
Prior to the 1990s, natural chickenpox (caused by the varicella zoster virus) was a nearly universal childhood experience and, in children with normal immune systems, played out as a mild disease that conferred long-term immunity. In 1995, without any compelling medical reason to do so, the CDC added the chickenpox vaccine to the childhood vaccine schedule for 12- to 15-month-olds. In 2006, acknowledging the problem of waning vaccine effectiveness, it indicated that four- to six-year-old children needed to get a second (booster) shot. Read More...New Animal Study Reveals Aluminum Adjuvants Can Impair Social Behavior
First Experimental Study on Baby Mice Finds Autism-like Response to Common Vaccine Ingredient
A breakthrough study by scientists from the University of British Columbia in Vancouver, Canada has been published in the Journal of Inorganic Biochemistry demonstrating that significant correlations exist between rates of Autism Spectrum Disorder (ASD) and total aluminum adjuvants given to children through vaccines in several Western countries.
According to the authors of the study, Sneha K.S. Sheth, Yongling Li and Christopher A. Shaw, this is the first experimental study to demonstrate that aluminum adjuvants can impair social behavior if applied in the early period of postnatal development. These correlations satisfied eight out of nine Hill criteria for causality. Experimental studies have demonstrated a range of behavioral abnormalities in young mice after postnatal exposure to aluminium. To build on the team's previous work, the current study investigates the effect of aluminium adjuvants on social behavior in mice. Anomalies in social interaction are a key characteristic of those with ASD.
Vaccine Safety Project Trailer…Donate Now
J.B. Handley’s interview with Del Bigtree about the new groundbreaking study out now about the aluminum/vaccine link
New study: Aluminium in brain tissue in autism
Abstract
Autism spectrum disorder is a neurodevelopmental disorder of unknown aetiology. It is suggested to involve both genetic susceptibility and environmental factors including in the latter environmental toxins. Human exposure to the environmental toxin aluminium has been linked, if tentatively, to autism spectrum disorder. Herein we have used transversely heated graphite furnace atomic absorption spectrometry to measure, for the first time, the aluminium content of brain tissue from donors with a diagnosis of autism. We have also used an aluminium-selective fluor to identify aluminium in brain tissue using fluorescence microscopy. The aluminium content of brain tissue in autism was consistently high. The mean (standard deviation) aluminium content across all 5 individuals for each lobe were 3.82(5.42), 2.30(2.00), 2.79(4.05) and 3.82(5.17) μg/g dry wt. for the occipital, frontal, temporal and parietal lobes respectively. These are some of the highest values for aluminium in human brain tissue yet recorded and one has to question why, for example, the aluminium content of the occipital lobe of a 15 year old boy would be 8.74 (11.59) μg/g dry wt.? Aluminium-selective fluorescence microscopy was used to identify aluminium in brain tissue in 10 donors. While aluminium was imaged associated with neurones it appeared to be present intracellularly in microglia-like cells and other inflammatory non-neuronal cells in the meninges, vasculature, grey and white matter. The pre-eminence of intracellular aluminium associated with non-neuronal cells was a standout observation in autism brain tissue and may offer clues as to both the origin of the brain aluminium as well as a putative role in autism spectrum disorder.
Download Full Study Here
